Type 2 Diabetes and Oral Antihyperglycemic Drugs

Mizuno, Cássia S.; Chittiboyina, Amar G.; Kurtz, Theodore W.; Pershadsingh, Harrihar A.; Avery, Mitchell A.

doi:10.2174/092986708783330656

Cited by 112 publications

(22 citation statements)

References 129 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[106] Several studies have shown the involvement of potassium channels in the regulation of cancer cell proliferation and apoptosis, suggesting these channels as potential targets for cancer therapy. Glibenclamide like other SUs acts by binding to and inhibiting SURs, which are subunits of ATP-dependent potassium channels.…”

Section: Sulfonylureasmentioning

confidence: 99%

New insights into antidiabetic drugs: Possible applications in cancer treatment

et al. 2017

View full text Add to dashboard Cite

Globally at 2014, it was estimated that there was 347 million people with diabetes in which 90 percent of them were diagnosed with type 2 diabetes mellitus (T2DM). Although the association between diabetes mellitus and cancer risk was found about 100 years ago, the issue is not still clear. Many studies especially cohort and case-control studies have suggested a higher risk of cancer in patients with diabetes mainly in those with type 2 diabetes. Insulin concentration is high in these patients, and due to its mitogenic effects, it may be a possible hypotheses for higher risk of cancer in diabetic patients. Therefore, antidiabetic drugs, which are involved in insulin secretion and sensitivity, may have beneficial effects in cancer treatment. Several groups of drugs with different mechanisms of action, mostly prescribed orally, are used for the treatment of type 2 diabetes mellitus including, insulin sensitizers (thiazolidinediones), insulin secretagogues (sulfonylureas), and biguanides. In this review, the possible effects of antidiabetic drugs (biguanides, thiazolidinediones, and sulfonylureas) and some of their mechanisms for overcoming cancer will be discussed.

show abstract

Section: Sulfonylureasmentioning

confidence: 99%

New insights into antidiabetic drugs: Possible applications in cancer treatment

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Individuals with diabetes and other fatal debilitating diseases have been treated orally in traditional folk medicine with a variety of plant extracts for many years [16]. Natural medicinal drugs are reclaiming their position as the primary source of treatment opposed to the current and main forms of synthetic treatment [11].…”

Section: Introductionmentioning

confidence: 99%

Biosynthesis Of Bimetallic Au-Ag Nanoparticles Using Ocimum Basilicum (L.) With Antidiabetic And Antimicrobial Properties

Ramdas¹,

Mbatha²,

Gengan³

et al. 2015

Adv. Mater. Lett.

View full text Add to dashboard Cite

This study was aimed at developing a simple, eco-friendly and cost effective green chemistry method for the synthesis of bimetallic Au-Ag nanoparticles using Ocimum basilicum aqueous leaf and flower extracts, respectively as the natural reducing agents. The successive reduction of chloroauric acid and silver nitrate led to the formation of Au-Ag nanoparticles within 10 min at room temperature, suggesting a higher reaction rate than chemical methods involved in the synthesis. Stable, spherical nanoparticles with well-defined dimensions of average size of 3-25 nm was confirmed by UV-Visible spectroscopy, TEM, SEM-EDX, DLS, and zeta potential, whilst, FTIR in combination with GC-MS analyzed the functional groups adhered to the surface of the nanoparticles. The colloidal suspension displayed enhanced antihyperglycemic activity at 69.97 ± 3.42% (leaf) against α-amylase (from porcine) and at 85.77 ± 5.82% (flower) against Bacillus stearothermophilus α-glucosidase than that of acarbose and their respective crude extracts. Furthermore, revealed good antibacterial activity against bacterial species Staphylococcus aureus, Escherichia coli, Bacillus subtilis and Pseudomonas aeruginosa.

show abstract

“…Traditionally, noninsulin-dependent T2DM is pharmacologically managed with oral antidiabetic agents from several different classes, which includes agents that increase insulin secretion, improve insulin action, and delay absorption of carbohydrates. The more recent incretin-based therapies address a previously unmet need in the diabetic therapeutic approach by modulating glucose supply [21–23]. Their pharmacological action is based on gut incretin hormones, the glucose-dependent insulinotropic peptide (GIP), and the glucagon like peptide-1 (GLP-1), which appear to be malfunctioning in T2DM and have important effects on insulin and glucagon secretion [24, 25].…”

Section: Introductionmentioning

confidence: 99%

Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)

Mega

Lemos

Vala

et al. 2011

Experimental Diabetes Research

143

113

View full text Add to dashboard Cite

This study was performed to assess the effect of chronic low-dose sitagliptin, a dipeptidyl peptidase 4 inhibitor, on metabolic profile and on renal lesions aggravation in a rat model of type-2 diabetic nephropathy, the Zucker diabetic fatty (ZDF) rat. Diabetic and obese ZDF (fa/fa) rats and their controls ZDF (+/+) were treated for 6 weeks with vehicle (control) or sitagliptin (10 mg/kg/bw). Blood/serum glucose, HbA1c, insulin, Total-c, TGs, urea, and creatinine were assessed, as well as kidney glomerular and tubulointerstitial lesions (interstitial fibrosis/tubular atrophy), using a semiquantitative rating from 0 (absent/normal) to 3 (severe and extensive damage). Vascular lesions were scored from 0–2. Sitagliptin in the diabetic rats promoted an amelioration of glycemia, HbA1c, Total-c, and TGs, accompanied by a partial prevention of insulinopenia. Furthermore, together with urea increment prevention, renal lesions were ameliorated in the diabetic rats, including glomerular, tubulointerstitial, and vascular lesions, accompanied by reduced lipid peroxidation. In conclusion, chronic low-dose sitagliptin treatment was able to ameliorate diabetic nephropathy, which might represent a key step forward in the management of T2DM and this serious complication.

show abstract

Type 2 Diabetes and Oral Antihyperglycemic Drugs

Cited by 112 publications

References 129 publications

New insights into antidiabetic drugs: Possible applications in cancer treatment

New insights into antidiabetic drugs: Possible applications in cancer treatment

Biosynthesis Of Bimetallic Au-Ag Nanoparticles Using Ocimum Basilicum (L.) With Antidiabetic And Antimicrobial Properties

Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)

Contact Info

Product

Resources

About